The Swiss model predicted the largest cost saving following the introduction of BUCCOLAM.
The likelihood of individuals with classic MODY criteria having a mutation in HNF1A, HNF4A, or GCK is nearly 50% (3), a prevalence at which genetic testing for MODY would be predicted to be cost saving in our model.
The model predicts Aprokam is cost saving compared with purchased PFS, with a modest increase compared prepared PFS over 5 years.
The dollars saved annually were calculated by subtracting the cost of dengue in MID cities from the predicted cost of dengue if MID were not implemented.
Results: The model predicts that PCV7 vaccination in the US is cost saving for a normal influenza season, reducing pneumococcal-related costs by $1.6 billion.
The model predicts that PCV7 vaccination in the US is cost saving for a normal influenza season, reducing pneumococcal-related costs by $1.6 billion.
As a result, compared to the additional construction cost, the average cost saving potentials of the 1st-BEER-certified MFHCs in Groups 1, 2, and 3 were predicted to be 3.77%, 2.78%, and 2.87%, respectively.
Scenario 1 is predicted to produce a national saving of 5% (£162,258) for in-house tests with a zero royalty fee (£16.25); and virtually no cost saving if the royalty fee is £2.00 (threshold fee is £2.18 per sample).
